Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects

Pharmacology and Therapeutics

Volumn 113, Issue 2, 2007, Pages 378-393

  Miida, Takashi ^a   Takahashi, Akihiro ^a   Ikeuchi, Takeshi ^b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Beta amyloid; Ischemic stroke; LR11 SorLA; Subarachnoid hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID PRECURSOR PROTEIN; ATORVASTATIN; CERIVASTATIN; CLOPIDOGREL; DONEPEZIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; CYTOTOXICITY; DEMENTIA; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INFLAMMATION; NEUROFIBRILLARY TANGLE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; SUBARACHNOID HEMORRHAGE; THROMBOCYTE ACTIVATION; VASOSPASM;

ANIMALS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; CLINICAL TRIALS; DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 33846450284     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.09.003     Document Type: Review

References (159)

1. Abad-Rodriguez J., Ledesma M.D., Craessaerts K., Perga S., Medina M., Delacourte A., et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167 (2004) 953-960
2. Amarenco P., Labreuche J., Lavallée P., and Touboul P.-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
3. Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J., et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 102 (2005) 13461-13466
4. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
5. Bilz S., Wagner S., Schmitz M., Bedynek A., Keller U., and Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 45 (2004) 174-185
6. Björkhem I., Lütjohann D., Diczfalusy U., Ståhle L., Ahlborg G., and Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39 (1998) 1594-1600
7. Blennow K., de Leon M., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
8. Bodin S., Giuriato S., Ragab J., Humbel B.M., Viala C., Vieu C., et al. Production of phosphatidylinositol 3,4,5-trisphosphate and phosphatidic acid in platelet rafts: evidence for a critical role of cholesterol-enriched domains in human platelet activation. Biochemistry 40 (2001) 15290-15299
9. Böhm C., Seibel N.M., Henkel B., Steiner H., Haass C., and Hampe W. SorLA signaling by regulated intramembrane proteolysis. J Biol Chem 281 (2006) 14547-14553
10. Brown M.S., and Goldstein J.L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89 (1997) 331-340
11. Bujo H., and Saito Y. Modulation of smooth muscle cell migration by members of the low-density lipoprotein receptor family. Arterioscler Thromb Vasc Biol 26 (2006) 1246-1252
12. Bussolati B., Deregibus M.C., Fonsato V., Doublier S., Spatola T., Procida S., et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16 (2005) 1936-1947
13. Casani L., Sanchez-Gomez S., Vilahur G., and Badimon L. Pravastatin reduces thrombogenicity by mechanisms beyond plasma cholesterol lowering. Thromb Haemost 94 (2005) 1035-1041
14. Chong T., Naples M., Federico L., Taylor D., Smith G.J., Cheung R.C., et al. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Atherosclerosis 185 (2006) 21-31
15. Cole S.L., Grudzien A., Manhart I.O., Kelly B.L., Oakley H., and Vassar R. Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 280 (2005) 18755-18770
16. Colhoun H.M., et al., for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
17. Cordle A., and Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate-amyloid-induced microglial inflammatory responses. J Neurosci 25 (2005) 299-307
18. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280 (2005) 34202-34209
19. Coull A.J., Lovett J.K., Rothwell P.M., and for the Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 328 (2004) 326
20. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques implications for plaque stabilization. Circulation 103 (2001) 926-933
21. Demeester N., Castro G., Desrumaux C., De Geitere C., Fruchart J.C., Santens P., et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res 41 (2000) 963-974
22. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the brain. Curr Opin Lipidol 12 (2001) 105-112
23. Dietschy J.M., and Turley S.D. Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45 (2004) 1375-1397
24. Dietschy J.M., Turley S.D., and Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 34 (1993) 1637-1659
25. Dujovne C.A., et al., for Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1092-1097
26. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352 (1998) 1801-1807
27. Edwards P.A., and Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68 (1999) 157-185
28. Ehrenstein M.R., Jury E.C., and Mauri C. Statins for atherosclerosis-as good as it gets?. N Engl J Med 352 (2005) 73-75
29. Eliasziw M., et al., for the North American Symptomatic Carotid Endarterectomy Trial Group. Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. CMAJ 170 (2004) 1105-1109
30. Ellis C.A., Malik A.B., Gilchrist A., Hamm H., Sandoval R., Voyno-Yasenetskaya T., et al. Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway. J Biol Chem 274 (1999) 13718-13727
31. Endo A., Kuroda M., and Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72 (1976) 323-326
32. Endo A., Kuroda M., and Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 29 (1976) 1346-1348
33. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., and Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 83 (1998) 683-690
34. Fagan A.M., Bu G., Sun Y., Daugherty A., and Holtzman D.M. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271 (1996) 30121-30125
35. Feistritzer C., Lenta R., and Riewald M. Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost 3 (2005) 2798-2805
36. Fenton II J.W., Brezniak D.V., Ofosu F.A., Shen G.X., Jacobson J.R., and Garcia J.G.N. Statins and thrombin. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 115-120
37. Ferro D., Basili S., Alessandri C., Cara D., and Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149 (2000) 111-116
38. Förster E., Jossin Y., Zhao S., Chai X., Frotscher M., and Goffinet A.M. Recent progress in understanding the role of Reelin in radial neuronal migration, with specific emphasis on the dentate gyrus. Eur J Neurosci 23 (2006) 901-909
39. Fujino H., Saito T., Tsunenari Y., and Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin-determining the best animal model for human CYP and UGT activities. Drug Metab Drug Interac 20 (2004) 25-42
40. Furman C., Copin C., Kandoussi M., Davidson R., Moreau M., McTaggiart F., et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 174 (2004) 93-98
41. García M.J., Reinoso R.F., Sánchez Navarro A., and Prous J.R. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 25 (2003) 457-481
42. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378-3384
43. Giroud M., Creisson E., Fayolle H., Andre N., Becker F., Martin D., et al. Risk factors for primary cerebral hemorrhage: a population-based study-the stroke registry of Dijon. Neuroepidemiology 14 (1995) 20-26
44. Gotto Jr. A.M. Management of dyslipidemia. Am J Med 112 Suppl 8A (2002) 10S-18S
45. Greenwood J., Steinman L., and Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6 (2006) 358-370
46. Hayashi H., Campenot R.B., Vance D.E., and Vance J.E. Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J Biol Chem 279 (2004) 14009-14015
47. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
48. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
49. Hernàndez-Perera O., Pèrez-Sala D., Navarro-Antolín J., Sànchez-Pascuala R., Hernàndez G., Díaz C., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101 (1998) 2711-2719
50. Hirano M., Maeda K., Matsushima S., Nozaki Y., Kusuhara H., and Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68 (2005) 800-807
51. Hirayama S., Miida T., Obayashi K., Yamazaki F., Yamazaki-Sakurai M., Ito M., et al. Effect of apolipoprotein E (apoE) phenotype on the apoE content of CSF-HDL in children. Chin Chim Acta 356 (2005) 110-116
52. Horton J.D., Goldstein J.L., and Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2003) 1125-1131
53. Igel M., Sudhop T., and von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 42 (2002) 835-845
54. Ikeuchi T., and Sisodia S.S. Cell-free generation of the Notch1 intracellular domain (NICD) and APP-CTFγ: evidence for distinct intramembranous γ-secretase activities. Neuro Mol Med 1 (2002) 43-54
55. Ikeuchi T., and Sisodia S.S. The notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent γ-secretase cleavage. J Biol Chem 278 (2003) 7751-7754
56. Ishigami M., Honda T., Takasaki W., Ikeda T., Komai T., Ito K., et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29 (2001) 282-288
57. Jacobson J.R., Dudek S.M., Birukov K.G., Ye S.Q., Grigoryev D.N., Girgis R.E., et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 30 (2004) 662-670
58. Jadhav S.B., and Jain G.K. Statins and osteoporosis: new role for old drugs. J Pharm Pharmacol 58 (2006) 3-18
59. Jiang M., Bujo H., Zhu Y., Yamazaki H., Hirayama S., Kanaki T., et al. Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochem Biophys Res Commun 348 (2006) 1367-1377
60. Johnston S.C., Gress D.R., Browner W.S., and Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 (2000) 2901-2906
61. Jurevics H., and Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64 (1995) 895-901
62. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33 (1999) 234-241
63. Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., and Coughlin S.R. Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103 (1999) 879-887
64. Kanaki T., Bujo H., Hirayama S., Tanaka K., Yamazaki H., Seimiya K., et al. Developmental regulation of LR11 expression in murine brain. DNA Cell Biol 17 (1998) 647-657
65. Kennedy J., Eliasziw M., Hill M.D., and Buchan A.M. The Fast Assessment of Stroke and Transient ischemic attack to prevent Early Recurrence (FASTER) Trial. In: Biller J. (Ed). Seminars in Cerebrovascular Diseases and Stroke Vol. 3/1 (2003) 25-30
66. Kojro E., Gimpl G., Lammich S., März W., and Falk Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci U S A 98 (2001) 5815-5820
67. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
68. Larose E., and Ganz P. Statins and endothelial dysfunction. Semin Vasc Med 4 (2004) 333-346
69. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
70. Laufs U., Gertz K., Dirnagl U., Böhm M., Nickenig G., and Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942 (2002) 23-30
71. Lee E., Ryan S., Birmingham B., Zalikowski J., March R., Ambrose H., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
72. Li G., Higdon R., Kukull W.A., Peskind E., Van Valen Moore K., Tsuang D., et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63 (2004) 1624-1628
73. Li Z., Dong X., Wang Z., Liu W., Deng N., Ding Y., et al. Regulation of PTEN by Rho small GTPases. Nat Cell Biol 7 (2005) 399-404
74. Linton M.F., Gish R., Hubl S.T., Bütler E., Esquivel C., Bry W.I., et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 88 (1991) 270-281
75. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
76. Lovett J.K., Dennis M.S., Sandercock P.A., Bamford J., Warlow C.P., and Rothwell P.M. Very early risk of stroke after a first transient ischemic attack. Stroke 34 (2003) e138-e140
77. Lund E.G., Guileyardo J.M., and Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A 96 (1999) 7238-7243
78. Lynch J.R., Wang H., McGirt M.J., Floyd F., Friedman A.H., Coon A.L., et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage results of a pilot randomized clinical trial. Stroke 36 (2005) 2024-2026
79. Mach F., Senouf D., Fontana P., Boehlen F., Reber G., Daali Y., et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 35 (2005) 476-481
80. McGirt M.J., Lynch J.R., Parra A., Sheng H., Pearlstein R., Laskowitz D.T., et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid homorrhage. Stroke 33 (2002) 2950-2956
81. McGirt M.J., Pradilla G., Legnani F.G., Thai Q.-A., Recinos P.F., and Tamargo R.J. Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery 58 (2006) 945-951
82. Miida T., Yamazaki F., Sakurai M., Wada R., Yamadera T., Asami K., et al. The apolipoprotein E content of HDL in cerebrospinal fluid is higher in children than in adults. Clin Chem 45 (1999) 1294-1296
83. Miida T., Hirayama S., and Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 11 (2004) 253-264
84. Miida T., Takahashi A., Tanabe N., and Ikeuchi T. Can statin therapy really reduce the risk of Alzheimer's disease and slow its progression?. Curr Opin Lipidol 16 (2005) 619-623
85. Miida T., Yamada T., Seino U., Ito M., Fueki Y., Takahashi A., et al. Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim Biophys Acta 1761 (2006) 424-433
86. Morgan A., Rerkasem K., Gallagher P., Zhang B., Morris G., Calder P., et al. Differences in matrix metalloprotease-1 and matrix metalloprotease-12 transcript levels among carotid atherosclerotic plaque stability. Stroke 35 (2004) 1310-1315
87. Morikawa S., Takabe W., Mataki C., Kanke T., Itoh T., Wada Y., et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9 (2002) 178-183
88. Mukhtar R.Y.A., and Reckless J.P.D. Statin-induced myositis: a commonly encountered or rare side effect?. Curr Opin Lipidol 16 (2005) 640-647
89. Muldoon M.F., Ryan C.M., Sereika S.M., Flory J.D., and Manuck S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 117 (2004) 823-829
90. Murugappa S., and Kunapuli S.P. The role of ADP receptors in platelet function. Front Biosci 11 (2006) 1977-1986
91. Nakamura H., et al., for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomized controlled trial. Lancet 368 (2006) 1155-1163
92. Niu S., Renfro A., Quattrocchi C.C., Sheldon M., and D'Arcangelo G. Reelin promotes hippocampal dendrite development through the VLDLR/apoER2-Dab1 pathway. Neuron 41 (2004) 71-84
93. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S., and Iwasaka T. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis 18 (2004) 177-185
94. Nomura E., Kohriyama T., Matsumoto M., and Kobayashi S. Clinical characteristics of first-ever atherothrombotic infarction or lacunar infarction with hyperlipidemia (J-STARS-C): an analysis of data from the stroke data bank of Japan. Intern Med 44 (2005) 1252-1257
95. Nordoy A., Svensson B., and Hansen J.B. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost 1 (2003) 690-697
96. Offe K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A., et al. The lipoprotein receptor LR11 regulates amyloid β production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 26 (2006) 1596-1603
97. Ofosu F.A. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfus Apheresis Sci 28 (2003) 265-268
98. Ogawa M., Miyata T., Nakajima K., Yagyu K., Seike M., Ikenaka K., et al. The reeler gene-associated antigen on Cajal-Retzius neurons is a crucial molecule for laminar organization of cortical neurons. Neuron 14 (1995) 899-912
99. Okumura K., Iseki K., Wakugami K., Kimura Y., Muratani H., Ikemiya Y., et al. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J 63 (1999) 53-58
100. Ozaki K., Yamamoto T., Ishibashi T., Matsubara T., Nishio M., and Aizawa Y. Regulation of endothelial nitric oxide synthase and endothelin-1 expression by fluvastatin in human vascular endothelial cells. Jpn J Pharmacol 85 (2001) 147-154
101. Parmar K.M., Nambudiri V., Dai G., Larman H.B., Gimbrone Jr. M.A., and Garcia-Cardena G. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 280 (2005) 26714-26719
102. Pederson T.R., Kjekshus J., Pyörälä K., Olsson A.G., Cook T.J., Musliner T.A., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 81 (1998) 333-335
103. Peverill R.E., Smolich J.J., Malan E., Goldstat R., and Davis S.R. Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. Maturitas 53 (2006) 158-165
104. Pfuetze K.D., and Dujovne C.A. Probucol. Curr Atheroscler Rep 2 (2000) 47-57
105. Pitas R.E., Boyles J.K., Lee S.H., Foss D., and Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E containing lipoproteins. Biochim Biophys Acta 917 (1987) 148-161
106. Pitas R.E., Boyles J.K., Lee S.H., Hui D., and Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E (LDL) receptors in the brain. J Biol Chem 262 (1987) 14352-14360
107. Plehn J.F., et al., for the Care Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 99 (1999) 216-223
108. Prisco D., Rogasi P.G., Paniccia R., Coppo M., Abbate R., Gensini G.F., et al. Altered lipid composition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia. Thromb Res 50 (1988) 593-604
109. Puccetti L., Pasqui A.L., Pastorelli M., Bova G., Cercignani M., Palazzuoli A., et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest 32 (2002) 901-908
110. Puccetti L., Pasqui A.L., Auteri A., and Bruni F. Mechanisms for antiplatelet action of statins. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 121-126
111. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., et al. Statin use and the risk of incident dementia. The Cardiovascular Health Study. Arch Neurol 62 (2005) 1047-1051
112. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7 (2000) 321-331
113. Rockwood K., Kirkland S., Hogan D.B., Chris MacKnight C., Merry H., Verreault R., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59 (2002) 223-227
114. i signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost 3 (2005) 1036-1041
115. Sata M., Nishimatsu H., Osuga J., Tanaka K., Ishizaka N., Ishibashi S., et al. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43 (2004) 1214-1220
116. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
117. Scherzer C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., et al. Loss of apolipoprotein E receptor LR11 in Alzheimer dseasei. Arch Neurol 61 (2004) 1200-1205
118. Schwartz G.G., et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
119. Serebruany V.L., Miller M., Pokov A.N., Malinin A.I., Lowry D.R., Tanguay J.F., et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol 97 (2006) 1332-1336
120. Sever P.S., et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
121. Shattil S.J., Anaya-Galindo R., Bennett J., Colman R.W., and Cooper R.A. Platelet hypersensitivity induced by cholesterol incorporation. J Clin Invest 55 (1975) 636-643
122. Shepherd J. Special report: highlight of the 75th European Atherosclerosis Society congress. Atherosclerosis 181 (2005) S1-S7
123. Shepherd J., et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
124. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.LEM., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
125. Simons M., Schwärzler F., Lütjohann D., Von Bergmann K., Beyreuther K., Dichgans J., et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52 (2002) 346-350
126. Skaletz-Rorowski A., and Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol 14 (2003) 599-603
127. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., et al. Atorvastatin for the Treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62 (2005) 753-757
128. Spoelgen R., von Arnim C.A.F., Thomas A.V., Peltan I.D., Koker M., Deng A., et al. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and β-secretase β-site APP-cleaving enzyme. J Neurosci 26 (2006) 418-428
129. Sprecher D.L. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol 86 12A (2000) 46L-50L
130. Suzuki Y., Yamamoto M., Wada H., Ito M., Nakano T., Sasaki Y., et al. Blood 93 (1999) 3408-3417
131. Taira K., Bujo H., Hirayama S., Yamazaki H., Kanaki T., Takahashi K., et al. LR11, a mosaic LDL receptor family member, mediates the uptake of apoE-rich lipoproteins in vitro. Arterioscler Thromb Vasc Biol 21 (2001) 1501-1506
132. Tamaru S., Fukuta T., Kaibuchi K., Matsuoka Y., Shiku H., and Nishikawa M. Rho-kinase induces association of adducin with cytoskeleton in platelet activation. Biochem Biophys Res Commun 332 (2005) 347-351
133. Tanzi R.E., and Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a gentic perspective. Cell 120 (2005) 545-555
134. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. New Engl J Med 355 (2006) 549-559
135. Tomizuka T., Yamamoto K., Hirai A., Tamura Y., and Yoshida S. Hypersensitivity to thromboxane A2 in cholesterol-rich human platelets. Thromb Haemost 64 (1990) 594-599
136. Trommsdorff M., Gotthardt M., Hiesberger T., Shelton J., Stockinger W., Nimpf J., et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and apoE receptor 2. Cell 97 (1999) 689-701
137. Tseng M.-Y., Czosnyka M., Richards H., Pickard J.D., and Kirkpatrick P.J. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 36 (2005) 1627-1632
138. Turley S.D., Burns D.K., and Dietschy J.M. Preferential utilization of newly synthesized cholesterol for brain growth in neonatal lambs. Am J Physiol 274 (1998) 1099-1105
139. Undas A., Brummel K.E., Musial J., Mann K.G., and Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103 (2001) 2248-2253
140. Urbich C., Dernbach E., Zeiher A.M., and Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res 90 (2002) 737-744
141. Vamvakopoulos J.E. Three's company: regulation of cell fate by statins. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 145-163
142. Van Aelst L., and D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 11 (1997) 2295-2322
143. Veillard N.R., and Mach F. Statins: the new aspirin?. Cell Mol Life Sci 59 (2002) 1771-1786
144. Vincent L., Soria C., Mirshahi F., Opolon P., Mishal Z., Vannier J.P., et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22 (2002) 623-629
145. Watanabe K., Sugiyama S., Kugiyama K., Honda O., Fukushima H., Koga H., et al. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 46 (2005) 2022-2030
146. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
147. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7 (2001) 687-692
148. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445
149. White C.M. A review of the pharmacological and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 42 (2002) 963-970
150. White H.D., Simes R.J., Anderson N.E., Hankey G.J., Watson J.D., Hunt D., et al. Pravastatin therapy and the risk of stroke. N Engl J Med 343 (2000) 317-326
151. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57 (2000) 1439-1443
152. Woo D., Kissela B.M., Khoury J.C., Sauerbeck L.R., Haverbusch M.A., Szaflarski J.P., et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke 35 (2004) 1360-1364
153. Yaffe K., Barrett-Connor E., Lin F., and Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59 (2002) 378-384
154. Yamauchi K., Tozuka M., Nakabayashi T., Sugano M., Hidaka H., Kondo Y., et al. Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin Chem 45 (1999) 497-504
155. Yang S.-A., Carpenter C.L., and Abrams C.S. Rho and Rho-kinase mediate thrombin-induced phosphatidylinositol 4-phosphate 5-kinase trafficking in platelets. J Biol Chem 279 (2004) 42331-42336
156. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb 10 (2003) 140-144
157. Yufu T., Hirano K., Bi D., Hirano M., Nishimura J., Iwamoto Y., et al. Rac1 regulation of surface expression of protease-activated receptor-1 and responsiveness to thrombin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2005) 1506-1511
158. Zandi P.P., Sparks L., Khachaturian A.S., Tschanz J., Norton M., Steinberg M., et al. Do statins reduce the risk of incident dementia and Alzheimer's disease? The Cache Study. Arch Gen Psychiatry 62 (2005) 217-224
159. Zhou Z., Rahme E., and Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 151 (2006) 273-781